关键药代动力学基因变异对 2 型糖尿病患者二甲双胍治疗反应的影响。
Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
机构信息
Department of Biotechnology, School of Life Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Department of Medicine,Yenepoya Medical College, Yenepoya Deemed to be University, Derlakatte, Mangalore, 570018, Karnataka, India.
出版信息
Pharmacogenomics. 2018 Jul 1;19(11):905-911. doi: 10.2217/pgs-2018-0041. Epub 2018 Jun 19.
AIM
Metformin, an oral hypoglycemic drug is the first line of treatment for Type 2 diabetes individuals. We studied the effect of critical gene single nucleotide polymorphisms on the glucose lowering effect of metformin.
METHOD
We performed a prospective study on 221 newly diagnosed, treatment-naive Type 2 diabetes subjects. Individuals were started with metformin monotherapy and followed up for 12 weeks.
RESULTS
Our association analysis revealed that SLC22A2 rs316019 and SLC47A2 rs12943590 were significantly associated with metformin drug response across co-dominant and dominant models, respectively. SLC22A2 rs316019 GG and SLC47A2 rs12943590 GA combined genotypes showed maximum average change in HbA1c level.
CONCLUSION
The present study proposes a role of SLC22A2 rs316019 and SLC47A2 rs12943590 in the pharmacokinetic action of metformin.
目的
二甲双胍是一种口服降糖药，是治疗 2 型糖尿病患者的一线药物。我们研究了关键基因单核苷酸多态性对二甲双胍降低血糖作用的影响。
方法
我们对 221 名新诊断、未经治疗的 2 型糖尿病患者进行了前瞻性研究。患者开始接受二甲双胍单药治疗，并随访 12 周。
结果
我们的关联分析显示，SLC22A2 rs316019 和 SLC47A2 rs12943590 分别在共显性和显性模型中与二甲双胍药物反应显著相关。SLC22A2 rs316019 GG 和 SLC47A2 rs12943590 GA 组合基因型显示 HbA1c 水平的平均变化最大。
结论
本研究提出了 SLC22A2 rs316019 和 SLC47A2 rs12943590 在二甲双胍药代动力学作用中的作用。
Zotero 插件